Tumours with NTRK gene fusion produce an altered TRK protein ... cells and slow the worsening of the disease. TRK fusion cancer can occur in any part of the body, including the lungs, thyroid, colon, ...

larotrectinib targets the NTRK fusion present in the tumor, making it effective across various cancer types that share this mutation. Researchers have previously conducted front-line research of ...

Vitrakvi received full FDA approval for treating NTRK gene fusion-positive solid tumors in adults and children, following its initial accelerated approval in 2018. The drug functions as a tyrosine ...

VITRAKVI ® is now fully approved for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance ...

The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid ... cleared for use via the Cancer Drugs Fund (CDF), which ...

"NTRK fusion-positive tumors represent a significant ... locally advanced or metastatic ROS1-positive non-small-cell lung cancer (NSCLC). It was approved by the FDA for this indication in November ...

VITRAKVI ® is now fully approved for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation ...

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK fusion-positive solid tumors. “This first full approval of an NTRK inhibitor ...